Research programme: cancer immunotherapies - ViaMuneAlternative Names: MTI
Latest Information Update: 24 Nov 2016
At a glance
- Originator ViaMune
- Class Cancer vaccines; Immunotherapies
- Mechanism of Action Immunomodulators; Mucin 1 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer